CRSP News and Press, CRISPR Therapeutics AG From 05/09/24

2024-05-09 09:32:14 ET Summary Crispr Therapeutics AG reported a net loss of $116.6 million in Q1 2024, but is expected to have significant earnings in the future as its gene editing therapy Casgevy gains commercial sales. Casgevy is approved to treat Sickle Cell Disease and Trans...

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of Americ...

2024-05-08 16:57:43 ET More on CRISPR Therapeutics Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade) Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics Crispr Therapeutics: Now Is The Time To Buy TD Cowen says sick...

-More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively,...

- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline with new pre-clinical programs utilizing LNP mediated delivery to the liver for refrac...

2024-05-06 12:44:19 ET More on bluebird bio bluebird bio, Inc. (BLUE) Q4 2023 Earnings Call Transcript bluebird bio Is Priced Below IP Value TD Cowen says sickle cell therapies may get higher CMS payments bluebird bio falls as accounting errors force restatem...

2024-05-05 08:00:00 ET As Wall Street embarks on the first full week of May, a diverse group of companies is set to report financial results. Notable names include The Walt Disney Company ( NYSE: DIS ), Palantir Technologies ( NYSE: PLTR ), Realty Income ( NYSE: ...

2024-05-03 15:00:00 ET More on the markets My Current View Of The Market: May 2024 Edition (Technical Analysis) SPY: The 'Value' From Equities Is Historically Low SPY: The Setup Looks Extremely Bearish 'Sell in May and go away': Does it apply in 2024? ...

2024-05-03 11:30:00 ET Summary Crispr Therapeutics AG stock has plunged deep into a bear market. The FOMO attributed to Crispr's Casgevy approvals is likely dissipated. Crispr has an expanding early-stage portfolio. Crispr is also gaining traction to improve Casgevy's safety p...

2024-05-02 07:15:00 ET The phrase "the golden age of biotech" was somewhat popular a few years ago but now seems largely forgotten. Regardless, biotech companies can be excellent long-term investment options for several reasons. Many are highly innovative corporations that develop break...